Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Office of Product Quality Ready To Go: New Structure Sends Strong Signal To Industry

This article was originally published in RPM Report

Executive Summary

It took a while, but the Office of Pharmaceutical Quality is finally ready to begin operations. Biopharma companies should recognize the declaration of FDA’s priorities, and respond accordingly.

Advertisement

Related Content

FDA Pharmaceutical Quality ‘Super Office’ Launches With Integrated Reviews
FDA Pharmaceutical Quality ‘Super Office’ Launches With Integrated Reviews
CDER Office of Pharmaceutical Quality Launches; Initial Impact On Manufacturers Is Minimal
FDA Pharmaceutical Quality Office Launches With Team-based Reviews
“Breakthrough” Means Breaking Down Bureaucracy
CDER’s New Quality Office Still Awaiting Final Sign Offs
FDA’s Woodcock to Head Office of Pharmaceutical Quality; New Details Emerge
Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba

Topics

Advertisement
UsernamePublicRestriction

Register

PS079652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel